
Bio-Techne Profits Surge 95% as High-Growth GMP Proteins Jump 50%
Bio-Techne CorporationDescription
What this story covers
Bio-Techne reported a 95% surge in GAAP operating income despite a 2% revenue dip. Growth was driven by a 50% increase in GMP proteins and mid-teens gains in Spatial Biology, alongside significant debt reduction and strategic divestitures.
Story snapshot
CompanyBio-Techne Corporation
TickerTECH
VariantStandard detailed
Duration12:49
Filing type8-K
PeriodQ3 2026
IndustryHealthcare & Pharmaceuticals
Accession0001104659-26-055887
Sources1
Full Story Script
Content not available for this story.